According to the WHO, there are more than 10,000 rare diseases caused by mutations of a single gene. Thankfully, for the millions of patients these diseases impact, advances in science and technology are enabling new treatment approaches. In fact, Evaluate Pharma indicates that there are nearly 1,000 companies with cell and gene therapies in varying stages of commercialization. Additionally, the overall market for rare diseases is expected to grow 10x between 2021 and 2026 in total sales.
In this 30-minute session, Robert Groebel, VP of Global Life Sciences Strategy at Definitive Healthcare will look the complex pathway to commercialization, highlight some of the key challenges and share best practice approaches to help ensure your therapies reach the patients that need them. Join live to learn:
- The 3 key challenges affecting the commercialization of cell and gene therapies
- 5 considerations on how to optimize your commercial process
- How to leverage real world evidence (RWE) to improve commercial intent
About the speaker
Robert Groebel, VP, Global Medical Strategy
Robert Groebel is the Global VP of Medical Strategy at Definitive Healthcare. He is recognized for his ability to create a strategic vision and accelerate innovation via technology. Most recently, he was the Global Vice President, Medical & Account Management Strategy at Veeva Systems. He has more than 25 years of healthcare experience holding global medical and commercial roles at both Boehringer Ingelheim and Shire Pharmaceuticals. In his current role, he guides commercial & medical affairs organizations globally to leverage technology, data, and analytics to enhance engagement, scientific, communications, and account management strategies in today’s increasingly complex healthcare landscape.